Decades ago, oncologists like Kenedi's doctor, "As a parent, when you see that CT scan up on the screen, you're completely breaking down," remembers her dad, Dylan. "Our doctor was in tears, trying to stay calm because he's got this."

In 2021, you met Kenedi Schoeneck and her family from Wisconsin. Kenedi was only six years old when she was diagnosed with a rare childhood malignancy in her kidney known as Wilms' tumor. Worse still, Kenedi's form of cancer did not survive. Patients like Kenedi are able to speak with such confidence. Four out of every five children with cancer are survivors.

"Cancer research requires time, patience and persistence," said Dr. Leuva, a hematology oncology fellow at SUNY Downstate Health Sciences University, was granted a Young Investigator Award to optimize drug precision medicine," says Dr. Leuva, whose ideas could change the course of cancer care and especially prostate cancer.

When a research grant is awarded, hope is born – for the scientists who get to work with patients and learn their stories. "I was moved by their stories," said one student. "It was an amazing privilege to work with patients and learn their stories." When a patient is diagnosed with prostate cancer, a doctor might recommend more treatment options, including hormone therapy. But now, the precision medicine revolution means scientists can study the specific genes of each prostate tumor, leading to more personalized treatments and better outcomes for patients. "That's the only way we can move closer to our vision of a world where every cancer is prevented or cured, and every survivor is healthy," said Dr. Leuva. "And even for those with cancer that cannot be cured, we can improve care and deliver hope."